Takeda Pharmaceutical Company Limited

Alumis Inc.

Other

Sichuan Haisco Pharmaceutical Co., Ltd.

Fronthera U.S. Pharmaceuticals LLC

Xizang Haisco Pharmaceutical Co., Ltd.

Esker Therapeutics, Inc.

C2 Pharmaceuticals, LLC

Bohan Jin

Qing Dong

Gene Hung

Stephen W Kaldor

Nicholas Scorah

Edcon Chang

Tony Gibson

Yao Li

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Thyroid hormone receptor agonists and uses thereof

Described herein are compounds, for example, substituted 1,2,4-triazoles, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as TYK2 inhibitors

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Substituted pyridazines as TYK2 inhibitors

Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TY-K2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Described herein are pyridine compounds of Formula (XIII) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation 

Substituted pyridines as TYK2 inhibitors

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.

Autotaxin inhibitors and uses thereof

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Apoptosis signal-regulating kinase inhibitors and uses thereof

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

Hemoglobin modifier compounds and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof which may be useful in the treatment and/or prevention of various conditions. The present invention also provides methods of preparing such compounds and compositions, and methods of using the same.

Compounds for the treatment of cancer and inflammatory diseases

Compositions, uses and methods for their preparation

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R, R, R, G, G, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K&#x3b4;.

Growing community of inventors

San Diego, CA, United States of America

Bohan Jin